Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CARsgen Files NDA for China Approval of CAR-T Based on Phase II Data

publication date: Dec 12, 2022

Shanghai CARsgen Therapeutics reported positive data from a pivotal China Phase I/II trial for its lead candidate, a fully human, autologous BCMA CAR T-cell product. The Zevor-cel trial enrolled 102 patients with multiple myeloma who had received at least three previous treatments. For all 102 patients, the median follow-up was 9 months and the Overall Response Rate was 92.2%, the rate of very good partial response or better was 85.3%, and the Complete Response Rate/strict Complete Response rate was 45.1%. CARsgen has filed an NDA for China approval of Zevor-cel in this indication. More details....

Stock Symbol: (HK: 2171)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital